SlideShare une entreprise Scribd logo
1  sur  9
PP_RDP_MA
MEDICATION ADHERENCE
Medication adherence is defined by the World Health Organization as "the degree to which
the person’s behaviour corresponds with the agreed recommendations from a health care
provider."
Though the terms adherence and compliance are synonymously used adherence differs from
compliance.
Compliance is the extent to which a patient’s behaviour matches the prescriber’s advice.
The Term COMPLIANCE has come into disfavour because it suggests that a person is
passively following a doctor's orders, rather than actively collaborating in the treatment
process.
• Adherence, on the other hand, requires the person's agreement to the recommendations
for therapy.
PERSISTENCE is defined as the ability of a person to continue taking medications for the
intended course of therapy. In the case of chronic diseases, the appropriate course of
therapy may be months, years, or even the person's lifetime.
A person is classified as non-persistent if he or she never fills a prescription or stops taking a
prescription prematurely.
Discussing the intended course of therapy when medications are first started has been shown
to be an important factor in keeping people persistent with a medication regimen.
PP_RDP_MA
Adherence is a multidimensional phenomenon determined by the interplay of five sets of
factors, termed "dimensions" by the World Health Organization:
1. Social/economic factors
2. Provider-patient/health care system factors
3. Condition-related factors
4. Therapy-related factors
5. Patient-related factors
1. SOCIALAND ECONOMIC DIMENSION
1. Limited English language proficiency
2. Low health literacy
3. Lack of family or social support network
4. Unstable living conditions; homelessness
5. Burdensome schedule
6. Limited access to health care facilities
7.Lack of health care insurance
8.Inability or difficulty accessing pharmacy
PP_RDP_MA
9.Medication cost
10.Cultural and lay beliefs about illness and treatment
11.Elder abuse
2. HEALTH CARE SYSTEM DIMENSION
1. Provider-patient relationship
2. Provider communication skills (contributing to lack of patient knowledge or understanding
of the treatment regimen)
3. Disparity between the health beliefs of the health care provider and those of the patient
4.Lack of positive reinforcement from the health care provider
5.Weak capacity of the system to educate patients and provide follow-up
6.Lack of knowledge on adherence and of effective interventions for improving it
7.Patient information materials written at too high literacy level
8.Restricted formularies; changing medications covered on formularies
9.High drug costs, co-payments, or both
10.Poor access or missed appointments
11.Long wait times
12.Lack of continuity of care
3. CONDITION-RELATED DIMENSION
1. Chronic conditions
2. Lack of symptoms
3. Severity of symptoms
4. Depression
5. Psychotic disorders
6. Mental retardation/developmental disability
4. THERAPY-RELATED DIMENSION
1. Complexity of medication regimen (number of daily doses; number of concurrent
medications)
2. Treatment requires mastery of certain techniques (injections, inhalers)
3. Duration of therapy
4. Frequent changes in medication regimen
PP_RDP_MA
5. Lack of immediate benefit of therapy
6. Medications with social stigma attached to use
7.Actual or perceived unpleasant side effects
8.Treatment interferes with lifestyle or requires significant behavioural changes
5. PATIENT-RELATED DIMENSION PHYSICAL FACTORS:
1. Visual impairment
2. Hearing impairment
3. Cognitive impairment
4. Impaired mobility or dexterity
5. Swallowing problems
Psychological/Behavioural Factors:
1. Knowledge about disease
2. Perceived risk/susceptibility to disease
3. Understanding reason medication is needed
4. Expectations or attitudes toward treatment
5. Perceived benefit of treatment
6. Confidence in ability to follow treatment regimen
7.Motivation
8.Fear of possible adverse effects
9.Fear of dependence
10.Feeling stigmatized by the disease
11.Frustration with health care providers
12.Psychosocial stress, anxiety, anger
13.Alcohol or substance abuse
MEASURING ADHERENCE
There are several ways to measure medication adherence.
1.Medication event monitoring systems (MEMS):- These are the most accurate method of
measuring adherence because they record the date and time the medication bottle was opened
through microprocessor technology embedded in the cap.
PP_RDP_MA
Advantages with microprocessor: -
1. erroneous/not faith/falls., because pt may remove more than one dose
2. Very expensive & different devices are needed for each medication
3.Therefore it is an impractical way to determine adherence in clinical practice.
2.Patient self-reports is easiest method when adherence is being assessed, open-ended
questions should be asked. Instead of asking, “Are you taking your medications?” the HCP
should phrase the question along the lines of, “How many times in the past week (month) have
you skipped your medications?”
3. Pill counts
4.Pharmacy databases or refill rates, and Blood levels which also are employed in
research, are more feasible options for clinical practice
6.Morisky’s Medication Adherence Scale (MMAS) It was designed to distinguish poorly
adherent patients from those with medium- to-high adherence to their antihypertensive
regimen.
PP_RDP_MA
MMAS consists of questions addressing multiple reasons for non-adherence.. e.g., because
regimen complexity can lead to noncompliance.
The scale contains a question assessing whether the patient feels hassled (trouble/Tense)
about his or her regimen
• Since patients tend to give their HCPs positive answers to please them, the questions in
Morisky’s study were phrased to avoid this bias.
• Each question measures a specific medication- taking behavior rather than adherence or
compliance behavior.
7. Mobile apps that periodically remind patients to take their medications, connect patients
and pharmacists for collaborative care and initiate notifications to a patient’s family and friends
if the person has not taken prescribed medications.
PP_RDP_MA
PP_RDP_MA
8. Innovative medication packaging as offered by PillPack, designed to help patients manage
multiple medications through convenient packaging, modern technology and personalized
service.
PP_RDP_MA
Methods Can Improve Medication Adherence by Pharmacists
1. Use Kitchen Table Consults
2. Improve Pharmacy Work Flow
3. Simplify Patients’ Medications
4. Identify Reasons for Medication Non- adherence
5. Ask Patients Specific Questions About Their Medication
ROLE OF THE PHARMACIST
• While medication dispensing is the best- known function of the pharmacist, pharmacists—
through counselling, medication therapy management (MTM), disease-state management, and
other means—can play a pivotal role in patient care.
• There are opportunities in every type of pharmacy practice to improve patients’
adherence and therapeutic outcomes, and pharmacists must embrace and act on them.
1. Patient Education
2.Dosing simplification and minimization of adverse effects are extremely successful
strategies for improving adherence.
3.Preparing a dosing card containing only the most essential elements of the patient’s
medications can be highly beneficial It can be extremely helpful for patients who take
many medications or who have cognitive barriers.
4. Reminder calls, texts, or e-mails are helpful for many patients, especially those
with busy lifestyles. Automatic refills are a useful strategy
• Whatever the barriers to adherence may be, the only way to assess them is to talk to the
patient.
• The pharmacist needs to be diligent (pay attention) about including the patient in the
treatment experience.
• The more trust the patient has in the pharmacist, the more he or she will open up and
disclose any apprehensions or difficulties about taking his or her medication. Only then
can the pharmacist play an integral role in improving a patient’s adherence.

Contenu connexe

Tendances

c. Over the counter (OTC) sales.pptx
c. Over the counter (OTC) sales.pptxc. Over the counter (OTC) sales.pptx
c. Over the counter (OTC) sales.pptxAnusha Are
 
Patient counselling clinical pharmacy
Patient counselling clinical pharmacyPatient counselling clinical pharmacy
Patient counselling clinical pharmacyDr Asish Kumar Saha
 
Clinical Pharmacy.pptx
Clinical Pharmacy.pptxClinical Pharmacy.pptx
Clinical Pharmacy.pptxAfroj Shaikh
 
Adverse Drug Reactions (ADR)- Ravinandan A P
Adverse Drug Reactions (ADR)- Ravinandan  A PAdverse Drug Reactions (ADR)- Ravinandan  A P
Adverse Drug Reactions (ADR)- Ravinandan A PRavinandan A P
 
ADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptx
ADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptxADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptx
ADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptxShivaji University
 
Therapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A PTherapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A PRavinandan A P
 
Pharmacy & Therapeutics Committee.ppt
Pharmacy & Therapeutics Committee.pptPharmacy & Therapeutics Committee.ppt
Pharmacy & Therapeutics Committee.pptRavinandan A P
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
4. Community Pharmacy.pptx
4. Community Pharmacy.pptx4. Community Pharmacy.pptx
4. Community Pharmacy.pptxMangeshBansod2
 
Patient counselling
Patient counselling Patient counselling
Patient counselling Harshita Jain
 
Factors affecting medication adherence
Factors affecting medication adherence Factors affecting medication adherence
Factors affecting medication adherence Ramesh Ganpisetti
 
Unit 1 Hospital by Ravinandan A P 2024.pptx
Unit 1 Hospital by Ravinandan A P 2024.pptxUnit 1 Hospital by Ravinandan A P 2024.pptx
Unit 1 Hospital by Ravinandan A P 2024.pptxRavinandan A P
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
Over the counter (OTC) Medications
Over the counter (OTC) MedicationsOver the counter (OTC) Medications
Over the counter (OTC) MedicationsPharmtechfau
 
Budget - Hospital Budget - Unit: 4 (a) Ravinandan A P
Budget - Hospital Budget - Unit: 4 (a) Ravinandan A PBudget - Hospital Budget - Unit: 4 (a) Ravinandan A P
Budget - Hospital Budget - Unit: 4 (a) Ravinandan A PRavinandan A P
 

Tendances (20)

c. Over the counter (OTC) sales.pptx
c. Over the counter (OTC) sales.pptxc. Over the counter (OTC) sales.pptx
c. Over the counter (OTC) sales.pptx
 
over the counter drugs
over the counter drugs over the counter drugs
over the counter drugs
 
Patient counselling clinical pharmacy
Patient counselling clinical pharmacyPatient counselling clinical pharmacy
Patient counselling clinical pharmacy
 
Clinical Pharmacy.pptx
Clinical Pharmacy.pptxClinical Pharmacy.pptx
Clinical Pharmacy.pptx
 
OTC MEDICATION
OTC MEDICATION OTC MEDICATION
OTC MEDICATION
 
Adverse Drug Reactions (ADR)- Ravinandan A P
Adverse Drug Reactions (ADR)- Ravinandan  A PAdverse Drug Reactions (ADR)- Ravinandan  A P
Adverse Drug Reactions (ADR)- Ravinandan A P
 
ADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptx
ADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptxADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptx
ADR MONITORING IN COMMUNITY PHARMACY ^0 RESEARCH.pptx
 
community pharmacy
community pharmacycommunity pharmacy
community pharmacy
 
Therapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A PTherapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A P
 
Pharmacy & Therapeutics Committee.ppt
Pharmacy & Therapeutics Committee.pptPharmacy & Therapeutics Committee.ppt
Pharmacy & Therapeutics Committee.ppt
 
Drug Information.
Drug Information.Drug Information.
Drug Information.
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
4. Community Pharmacy.pptx
4. Community Pharmacy.pptx4. Community Pharmacy.pptx
4. Community Pharmacy.pptx
 
Patient counselling
Patient counselling Patient counselling
Patient counselling
 
Factors affecting medication adherence
Factors affecting medication adherence Factors affecting medication adherence
Factors affecting medication adherence
 
HOSPITAL DRUG POLICY.pptx
HOSPITAL DRUG POLICY.pptxHOSPITAL DRUG POLICY.pptx
HOSPITAL DRUG POLICY.pptx
 
Unit 1 Hospital by Ravinandan A P 2024.pptx
Unit 1 Hospital by Ravinandan A P 2024.pptxUnit 1 Hospital by Ravinandan A P 2024.pptx
Unit 1 Hospital by Ravinandan A P 2024.pptx
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
Over the counter (OTC) Medications
Over the counter (OTC) MedicationsOver the counter (OTC) Medications
Over the counter (OTC) Medications
 
Budget - Hospital Budget - Unit: 4 (a) Ravinandan A P
Budget - Hospital Budget - Unit: 4 (a) Ravinandan A PBudget - Hospital Budget - Unit: 4 (a) Ravinandan A P
Budget - Hospital Budget - Unit: 4 (a) Ravinandan A P
 

Similaire à Improve Medication Adherence

Patient medication adherence
Patient medication adherencePatient medication adherence
Patient medication adherenceRana Pelluri
 
Medication adherence
Medication adherenceMedication adherence
Medication adherenceChanda Ranjan
 
Patient medication adhereance
Patient medication adhereancePatient medication adhereance
Patient medication adhereanceRafi Bhat
 
Medication Adherence.pptx
Medication Adherence.pptxMedication Adherence.pptx
Medication Adherence.pptxAmeena Kadar
 
MEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptxMEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptxAnilDhakal14
 
Medication Adherence.pdf
Medication Adherence.pdfMedication Adherence.pdf
Medication Adherence.pdfDr Ravikiran S
 
Medication Adherence , setting up directions ..
Medication Adherence , setting up directions .. Medication Adherence , setting up directions ..
Medication Adherence , setting up directions .. Ahmed Nouri
 
medication adherence.pdf
medication adherence.pdfmedication adherence.pdf
medication adherence.pdfArbeena Shakir
 
MEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPM
MEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPMMEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPM
MEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPMLipanjali Badhei
 
CLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptxCLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptxBimal Magar
 
Medication adherence
Medication adherenceMedication adherence
Medication adherenceSubhash Yende
 
Patient counseling
Patient counselingPatient counseling
Patient counselingManiz Joshi
 
1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptxyohanneswobie2
 
pharmacist patient education and counseling
pharmacist patient education and counseling pharmacist patient education and counseling
pharmacist patient education and counseling Hemat Elgohary
 
Medication Adherence.pptx
Medication Adherence.pptxMedication Adherence.pptx
Medication Adherence.pptxMangeshBansod2
 

Similaire à Improve Medication Adherence (20)

Patient medication adherence
Patient medication adherencePatient medication adherence
Patient medication adherence
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
Patient medication adhereance
Patient medication adhereancePatient medication adhereance
Patient medication adhereance
 
Medication Adherence.pptx
Medication Adherence.pptxMedication Adherence.pptx
Medication Adherence.pptx
 
Patient compliance Pdf
Patient compliance PdfPatient compliance Pdf
Patient compliance Pdf
 
MEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptxMEDICATION ADHERENCE.pptx
MEDICATION ADHERENCE.pptx
 
Medication Adherence.pdf
Medication Adherence.pdfMedication Adherence.pdf
Medication Adherence.pdf
 
Medication Adherence , setting up directions ..
Medication Adherence , setting up directions .. Medication Adherence , setting up directions ..
Medication Adherence , setting up directions ..
 
Patient counceling arghya
Patient counceling arghyaPatient counceling arghya
Patient counceling arghya
 
16 ab1t0022
16 ab1t002216 ab1t0022
16 ab1t0022
 
medication adherence
medication adherencemedication adherence
medication adherence
 
medication adherence.pdf
medication adherence.pdfmedication adherence.pdf
medication adherence.pdf
 
MEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPM
MEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPMMEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPM
MEDICATION ADHERENCE.pptx D. Pharm 2nd Year CPM
 
CLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptxCLINICAL PHARMACY.pptx
CLINICAL PHARMACY.pptx
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
Patient counseling
Patient counselingPatient counseling
Patient counseling
 
1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx1. Pharmacists in patient care.pptx
1. Pharmacists in patient care.pptx
 
PATIENT COUNSELLING.pptx
PATIENT COUNSELLING.pptxPATIENT COUNSELLING.pptx
PATIENT COUNSELLING.pptx
 
pharmacist patient education and counseling
pharmacist patient education and counseling pharmacist patient education and counseling
pharmacist patient education and counseling
 
Medication Adherence.pptx
Medication Adherence.pptxMedication Adherence.pptx
Medication Adherence.pptx
 

Plus de rishi2789

CHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdf
CHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdfCHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdf
CHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdfrishi2789
 
CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6rishi2789
 
CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6rishi2789
 
CHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdf
CHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdfCHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdf
CHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdfrishi2789
 
Drugs use in DM: Insulin AND OHG agents.pptx
Drugs use in DM: Insulin AND OHG agents.pptxDrugs use in DM: Insulin AND OHG agents.pptx
Drugs use in DM: Insulin AND OHG agents.pptxrishi2789
 
Drug use in Thyroid and Anti Thyroid analogue.pptx
Drug use in Thyroid and Anti Thyroid analogue.pptxDrug use in Thyroid and Anti Thyroid analogue.pptx
Drug use in Thyroid and Anti Thyroid analogue.pptxrishi2789
 
Basic concept of Endocrine pharmacology.pptx
Basic concept of Endocrine pharmacology.pptxBasic concept of Endocrine pharmacology.pptx
Basic concept of Endocrine pharmacology.pptxrishi2789
 
RISHITA_M.PHARM_CS.pptx
RISHITA_M.PHARM_CS.pptxRISHITA_M.PHARM_CS.pptx
RISHITA_M.PHARM_CS.pptxrishi2789
 
MEDICAL RESEARCH.pptx
MEDICAL RESEARCH.pptxMEDICAL RESEARCH.pptx
MEDICAL RESEARCH.pptxrishi2789
 
ANTI RA AGENTS.pptx
ANTI RA AGENTS.pptxANTI RA AGENTS.pptx
ANTI RA AGENTS.pptxrishi2789
 
Leukotrines.pdf
Leukotrines.pdfLeukotrines.pdf
Leukotrines.pdfrishi2789
 
5-HT and their Antagonist.pdf
5-HT and their Antagonist.pdf5-HT and their Antagonist.pdf
5-HT and their Antagonist.pdfrishi2789
 
Introduction to Autocids And Histamine and Antihistamine.pdf
Introduction to Autocids And Histamine and Antihistamine.pdfIntroduction to Autocids And Histamine and Antihistamine.pdf
Introduction to Autocids And Histamine and Antihistamine.pdfrishi2789
 
NEW DRUG DEVELOPMENT_RDP_2023.pdf
NEW DRUG DEVELOPMENT_RDP_2023.pdfNEW DRUG DEVELOPMENT_RDP_2023.pdf
NEW DRUG DEVELOPMENT_RDP_2023.pdfrishi2789
 
ADR-RDP-2023.pdf
ADR-RDP-2023.pdfADR-RDP-2023.pdf
ADR-RDP-2023.pdfrishi2789
 
PHARMACODYNAMICS_RDP_SEM-4.pdf
PHARMACODYNAMICS_RDP_SEM-4.pdfPHARMACODYNAMICS_RDP_SEM-4.pdf
PHARMACODYNAMICS_RDP_SEM-4.pdfrishi2789
 
RDP_PORTION ONLY_Question Bank_HAP-I_2023.pdf
RDP_PORTION ONLY_Question Bank_HAP-I_2023.pdfRDP_PORTION ONLY_Question Bank_HAP-I_2023.pdf
RDP_PORTION ONLY_Question Bank_HAP-I_2023.pdfrishi2789
 
Introduction to human body_RDP.pdf
Introduction to human body_RDP.pdfIntroduction to human body_RDP.pdf
Introduction to human body_RDP.pdfrishi2789
 
RDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdfRDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdfrishi2789
 

Plus de rishi2789 (20)

CHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdf
CHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdfCHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdf
CHEMOTHERAPY_RDP_G 5_CHLORAMPHENICOL.pdf
 
CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 4_CEPHALOSPORIN.pdf_SEM-6
 
CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6
CHEMOTHERAPY_RDP_G 3_PENICILLIN.pdf_SEM-6
 
CHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdf
CHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdfCHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdf
CHEMOTHERAPY_RDP_GENERAL PRINCIPLES OF CHEMOTHERAPY.pdf
 
Drugs use in DM: Insulin AND OHG agents.pptx
Drugs use in DM: Insulin AND OHG agents.pptxDrugs use in DM: Insulin AND OHG agents.pptx
Drugs use in DM: Insulin AND OHG agents.pptx
 
Drug use in Thyroid and Anti Thyroid analogue.pptx
Drug use in Thyroid and Anti Thyroid analogue.pptxDrug use in Thyroid and Anti Thyroid analogue.pptx
Drug use in Thyroid and Anti Thyroid analogue.pptx
 
Basic concept of Endocrine pharmacology.pptx
Basic concept of Endocrine pharmacology.pptxBasic concept of Endocrine pharmacology.pptx
Basic concept of Endocrine pharmacology.pptx
 
RISHITA_M.PHARM_CS.pptx
RISHITA_M.PHARM_CS.pptxRISHITA_M.PHARM_CS.pptx
RISHITA_M.PHARM_CS.pptx
 
MEDICAL RESEARCH.pptx
MEDICAL RESEARCH.pptxMEDICAL RESEARCH.pptx
MEDICAL RESEARCH.pptx
 
ANTI RA AGENTS.pptx
ANTI RA AGENTS.pptxANTI RA AGENTS.pptx
ANTI RA AGENTS.pptx
 
NSAIDS.pptx
NSAIDS.pptxNSAIDS.pptx
NSAIDS.pptx
 
Leukotrines.pdf
Leukotrines.pdfLeukotrines.pdf
Leukotrines.pdf
 
5-HT and their Antagonist.pdf
5-HT and their Antagonist.pdf5-HT and their Antagonist.pdf
5-HT and their Antagonist.pdf
 
Introduction to Autocids And Histamine and Antihistamine.pdf
Introduction to Autocids And Histamine and Antihistamine.pdfIntroduction to Autocids And Histamine and Antihistamine.pdf
Introduction to Autocids And Histamine and Antihistamine.pdf
 
NEW DRUG DEVELOPMENT_RDP_2023.pdf
NEW DRUG DEVELOPMENT_RDP_2023.pdfNEW DRUG DEVELOPMENT_RDP_2023.pdf
NEW DRUG DEVELOPMENT_RDP_2023.pdf
 
ADR-RDP-2023.pdf
ADR-RDP-2023.pdfADR-RDP-2023.pdf
ADR-RDP-2023.pdf
 
PHARMACODYNAMICS_RDP_SEM-4.pdf
PHARMACODYNAMICS_RDP_SEM-4.pdfPHARMACODYNAMICS_RDP_SEM-4.pdf
PHARMACODYNAMICS_RDP_SEM-4.pdf
 
RDP_PORTION ONLY_Question Bank_HAP-I_2023.pdf
RDP_PORTION ONLY_Question Bank_HAP-I_2023.pdfRDP_PORTION ONLY_Question Bank_HAP-I_2023.pdf
RDP_PORTION ONLY_Question Bank_HAP-I_2023.pdf
 
Introduction to human body_RDP.pdf
Introduction to human body_RDP.pdfIntroduction to human body_RDP.pdf
Introduction to human body_RDP.pdf
 
RDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdfRDP-CPM-CP-PP.pdf
RDP-CPM-CP-PP.pdf
 

Dernier

MENTAL STATUS EXAMINATION format.docx
MENTAL     STATUS EXAMINATION format.docxMENTAL     STATUS EXAMINATION format.docx
MENTAL STATUS EXAMINATION format.docxPoojaSen20
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991RKavithamani
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppCeline George
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon AUnboundStockton
 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsKarinaGenton
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Krashi Coaching
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 

Dernier (20)

MENTAL STATUS EXAMINATION format.docx
MENTAL     STATUS EXAMINATION format.docxMENTAL     STATUS EXAMINATION format.docx
MENTAL STATUS EXAMINATION format.docx
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website App
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon A
 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its Characteristics
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 

Improve Medication Adherence

  • 1. PP_RDP_MA MEDICATION ADHERENCE Medication adherence is defined by the World Health Organization as "the degree to which the person’s behaviour corresponds with the agreed recommendations from a health care provider." Though the terms adherence and compliance are synonymously used adherence differs from compliance. Compliance is the extent to which a patient’s behaviour matches the prescriber’s advice. The Term COMPLIANCE has come into disfavour because it suggests that a person is passively following a doctor's orders, rather than actively collaborating in the treatment process. • Adherence, on the other hand, requires the person's agreement to the recommendations for therapy. PERSISTENCE is defined as the ability of a person to continue taking medications for the intended course of therapy. In the case of chronic diseases, the appropriate course of therapy may be months, years, or even the person's lifetime. A person is classified as non-persistent if he or she never fills a prescription or stops taking a prescription prematurely. Discussing the intended course of therapy when medications are first started has been shown to be an important factor in keeping people persistent with a medication regimen.
  • 2. PP_RDP_MA Adherence is a multidimensional phenomenon determined by the interplay of five sets of factors, termed "dimensions" by the World Health Organization: 1. Social/economic factors 2. Provider-patient/health care system factors 3. Condition-related factors 4. Therapy-related factors 5. Patient-related factors 1. SOCIALAND ECONOMIC DIMENSION 1. Limited English language proficiency 2. Low health literacy 3. Lack of family or social support network 4. Unstable living conditions; homelessness 5. Burdensome schedule 6. Limited access to health care facilities 7.Lack of health care insurance 8.Inability or difficulty accessing pharmacy
  • 3. PP_RDP_MA 9.Medication cost 10.Cultural and lay beliefs about illness and treatment 11.Elder abuse 2. HEALTH CARE SYSTEM DIMENSION 1. Provider-patient relationship 2. Provider communication skills (contributing to lack of patient knowledge or understanding of the treatment regimen) 3. Disparity between the health beliefs of the health care provider and those of the patient 4.Lack of positive reinforcement from the health care provider 5.Weak capacity of the system to educate patients and provide follow-up 6.Lack of knowledge on adherence and of effective interventions for improving it 7.Patient information materials written at too high literacy level 8.Restricted formularies; changing medications covered on formularies 9.High drug costs, co-payments, or both 10.Poor access or missed appointments 11.Long wait times 12.Lack of continuity of care 3. CONDITION-RELATED DIMENSION 1. Chronic conditions 2. Lack of symptoms 3. Severity of symptoms 4. Depression 5. Psychotic disorders 6. Mental retardation/developmental disability 4. THERAPY-RELATED DIMENSION 1. Complexity of medication regimen (number of daily doses; number of concurrent medications) 2. Treatment requires mastery of certain techniques (injections, inhalers) 3. Duration of therapy 4. Frequent changes in medication regimen
  • 4. PP_RDP_MA 5. Lack of immediate benefit of therapy 6. Medications with social stigma attached to use 7.Actual or perceived unpleasant side effects 8.Treatment interferes with lifestyle or requires significant behavioural changes 5. PATIENT-RELATED DIMENSION PHYSICAL FACTORS: 1. Visual impairment 2. Hearing impairment 3. Cognitive impairment 4. Impaired mobility or dexterity 5. Swallowing problems Psychological/Behavioural Factors: 1. Knowledge about disease 2. Perceived risk/susceptibility to disease 3. Understanding reason medication is needed 4. Expectations or attitudes toward treatment 5. Perceived benefit of treatment 6. Confidence in ability to follow treatment regimen 7.Motivation 8.Fear of possible adverse effects 9.Fear of dependence 10.Feeling stigmatized by the disease 11.Frustration with health care providers 12.Psychosocial stress, anxiety, anger 13.Alcohol or substance abuse MEASURING ADHERENCE There are several ways to measure medication adherence. 1.Medication event monitoring systems (MEMS):- These are the most accurate method of measuring adherence because they record the date and time the medication bottle was opened through microprocessor technology embedded in the cap.
  • 5. PP_RDP_MA Advantages with microprocessor: - 1. erroneous/not faith/falls., because pt may remove more than one dose 2. Very expensive & different devices are needed for each medication 3.Therefore it is an impractical way to determine adherence in clinical practice. 2.Patient self-reports is easiest method when adherence is being assessed, open-ended questions should be asked. Instead of asking, “Are you taking your medications?” the HCP should phrase the question along the lines of, “How many times in the past week (month) have you skipped your medications?” 3. Pill counts 4.Pharmacy databases or refill rates, and Blood levels which also are employed in research, are more feasible options for clinical practice 6.Morisky’s Medication Adherence Scale (MMAS) It was designed to distinguish poorly adherent patients from those with medium- to-high adherence to their antihypertensive regimen.
  • 6. PP_RDP_MA MMAS consists of questions addressing multiple reasons for non-adherence.. e.g., because regimen complexity can lead to noncompliance. The scale contains a question assessing whether the patient feels hassled (trouble/Tense) about his or her regimen • Since patients tend to give their HCPs positive answers to please them, the questions in Morisky’s study were phrased to avoid this bias. • Each question measures a specific medication- taking behavior rather than adherence or compliance behavior. 7. Mobile apps that periodically remind patients to take their medications, connect patients and pharmacists for collaborative care and initiate notifications to a patient’s family and friends if the person has not taken prescribed medications.
  • 8. PP_RDP_MA 8. Innovative medication packaging as offered by PillPack, designed to help patients manage multiple medications through convenient packaging, modern technology and personalized service.
  • 9. PP_RDP_MA Methods Can Improve Medication Adherence by Pharmacists 1. Use Kitchen Table Consults 2. Improve Pharmacy Work Flow 3. Simplify Patients’ Medications 4. Identify Reasons for Medication Non- adherence 5. Ask Patients Specific Questions About Their Medication ROLE OF THE PHARMACIST • While medication dispensing is the best- known function of the pharmacist, pharmacists— through counselling, medication therapy management (MTM), disease-state management, and other means—can play a pivotal role in patient care. • There are opportunities in every type of pharmacy practice to improve patients’ adherence and therapeutic outcomes, and pharmacists must embrace and act on them. 1. Patient Education 2.Dosing simplification and minimization of adverse effects are extremely successful strategies for improving adherence. 3.Preparing a dosing card containing only the most essential elements of the patient’s medications can be highly beneficial It can be extremely helpful for patients who take many medications or who have cognitive barriers. 4. Reminder calls, texts, or e-mails are helpful for many patients, especially those with busy lifestyles. Automatic refills are a useful strategy • Whatever the barriers to adherence may be, the only way to assess them is to talk to the patient. • The pharmacist needs to be diligent (pay attention) about including the patient in the treatment experience. • The more trust the patient has in the pharmacist, the more he or she will open up and disclose any apprehensions or difficulties about taking his or her medication. Only then can the pharmacist play an integral role in improving a patient’s adherence.